This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

3 Plays on Health Care in China

China Jo-Jo Drugstores

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

This is a micro-cap stock and may not appeal to everyone. China Jo-Jo Drugstores (CJJD - Get Report) aims to become the "CVS of China," though it currently operates less than 50 retail pharmacies, with plans to grow the base to 75 by 2012. The company sells both traditional herbal remedies and modern pharmaceuticals, along with other wares typically found at a drugstore. Each store has a licensed physician on-site, paving the way for China Jo-Jo to start bolting urgent care facilities onto each of its drug stores.

Despite high levels of staffing, it's a very profitable business, with gross margins exceeding 50% and operating margins exceeding 20%. Each of those metrics is roughly twice as high as what U.S.-based drug stores typically post. That said, as the company grows margins are likely to come down to a moderate extent as the company opens stores in more competitive areas. Shares, which trade for less than half of the 52-week high, look quite cheap at around four times projected fiscal 2012 profit forecasts.

Action to Take: Each of these three stocks represents a unique growth and risk profile, so the most appealing name for you depends on your risk tolerance. Concord Medical appears to be the most solid business model, though it will likely take several years for shares to rise by a significant amount. American Oriental Bioengineering and China Jo-Jo Drugs are more speculative, but look significantly undervalued.

This article originally appeared on StreetAuthority.

At the time of publication, Sterman owned no positions in the stocks mentioned.
This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CJJD $1.66 0.00%
CCM $4.89 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs